These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

461 related items for PubMed ID: 34799964

  • 1. Letermovir conversion after valganciclovir treatment in cytomegalovirus high-risk abdominal solid organ transplant recipients may promote development of cytomegalovirus-specific cell mediated immunity.
    Jorgenson MR, Kleiboeker H, Garg N, Parajuli S, Mandelbrot DA, Odorico JS, Saddler CM, Smith JA.
    Transpl Infect Dis; 2022 Feb; 24(1):e13766. PubMed ID: 34799964
    [Abstract] [Full Text] [Related]

  • 2. The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients.
    Jorgenson MR, Descourouez JL, Garg N, Parajuli S, Mandelbrot DA, Odorico JS, Saddler CM, Smith JA.
    Transpl Infect Dis; 2021 Aug; 23(4):e13693. PubMed ID: 34309158
    [Abstract] [Full Text] [Related]

  • 3. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.
    Limaye AP, Budde K, Humar A, Vincenti F, Kuypers DRJ, Carroll RP, Stauffer N, Murata Y, Strizki JM, Teal VL, Gilbert CL, Haber BA.
    JAMA; 2023 Jul 03; 330(1):33-42. PubMed ID: 37279999
    [Abstract] [Full Text] [Related]

  • 4. Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients.
    Rho E, Näf B, Müller TF, Wüthrich RP, Schachter T, von Moos S.
    Clin Transplant; 2021 Nov 03; 35(11):e14401. PubMed ID: 34181768
    [Abstract] [Full Text] [Related]

  • 5. Conversion from cytomegalovirus universal prophylaxis with valganciclovir to the preemptive monitoring approach to manage leukopenia after kidney or pancreas transplantation.
    Jorgenson MR, Wong C, Descourouez JL, Saddler CM, Smith JA, Mandelbrot DA.
    Transpl Infect Dis; 2021 Aug 03; 23(4):e13617. PubMed ID: 33866643
    [Abstract] [Full Text] [Related]

  • 6. Letermovir prophylaxis in solid organ transplant-Assessing CMV breakthrough and tacrolimus drug interaction.
    Winstead RJ, Kumar D, Brown A, Yakubu I, Song C, Thacker L, Gupta G.
    Transpl Infect Dis; 2021 Aug 03; 23(4):e13570. PubMed ID: 33469975
    [Abstract] [Full Text] [Related]

  • 7. Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature.
    Hofmann E, Sidler D, Dahdal S, Bittel P, Suter-Riniker F, Manuel O, Walti LN, Hirzel C.
    Transpl Infect Dis; 2021 Jun 03; 23(3):e13515. PubMed ID: 33210830
    [Abstract] [Full Text] [Related]

  • 8. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
    Aryal S, Katugaha SB, Cochrane A, Brown AW, Nathan SD, Shlobin OA, Ahmad K, Marinak L, Chun J, Fregoso M, Desai S, King C.
    Transpl Infect Dis; 2019 Dec 03; 21(6):e13166. PubMed ID: 31487755
    [Abstract] [Full Text] [Related]

  • 9. Real-life use of letermovir prophylaxis for cytomegalovirus in heart transplant recipients.
    Saltiel G, Faure E, Assaf A, Chopin MC, Moreau F, Faure K, Goeminne C, Vuotto F.
    Clin Transplant; 2024 May 03; 38(5):e15327. PubMed ID: 38686437
    [Abstract] [Full Text] [Related]

  • 10. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection.
    Cherrier L, Nasar A, Goodlet KJ, Nailor MD, Tokman S, Chou S.
    Am J Transplant; 2018 Dec 03; 18(12):3060-3064. PubMed ID: 30286286
    [Abstract] [Full Text] [Related]

  • 11. Evaluating the efficacy and safety of letermovir compared to valganciclovir for the prevention of human cytomegalovirus disease in adult lung transplant recipients.
    Martinez S, Sindu D, Nailor MD, Cherrier L, Tokman S, Walia R, Goodlet KJ.
    Transpl Infect Dis; 2024 Jun 03; 26(3):e14279. PubMed ID: 38742601
    [Abstract] [Full Text] [Related]

  • 12. Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxis.
    Saullo JL, Baker AW, Snyder LD, Reynolds JM, Zaffiri L, Eichenberger EM, Ferrari A, Steinbrink JM, Maziarz EK, Bacchus M, Berry H, Kakoullis SA, Wolfe CR.
    J Heart Lung Transplant; 2022 Apr 03; 41(4):508-515. PubMed ID: 35031206
    [Abstract] [Full Text] [Related]

  • 13. Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients.
    Razonable RR.
    Clin Microbiol Infect; 2023 Sep 03; 29(9):1144-1149. PubMed ID: 36963566
    [Abstract] [Full Text] [Related]

  • 14. Letermovir as Salvage Therapy for Cytomegalovirus Infection in Transplant Recipients.
    Phoompoung P, Ferreira VH, Tikkanen J, Husain S, Viswabandya A, Kumar D, Humar A.
    Transplantation; 2020 Feb 03; 104(2):404-409. PubMed ID: 32000236
    [Abstract] [Full Text] [Related]

  • 15. Letermovir treatment for CMV infection in kidney and pancreas transplantation: A valuable option for complicated cases.
    Ortiz F, Lempinen M, Aaltonen S, Koivuviita N, Helanterä I.
    Clin Transplant; 2022 Feb 03; 36(2):e14537. PubMed ID: 34797574
    [Abstract] [Full Text] [Related]

  • 16. Letermovir for cytomegalovirus prophylaxis in high-risk heart transplant recipients.
    Golob S, Batra J, DeFilippis EM, Uriel M, Carey M, Gaine M, Mabasa A, Fried J, Raikelkar J, Restaino S, Hi Lee S, Latif F, Yuzefpolskaya M, Colombo PC, Choe J, Majure D, Jennings D, Pereira MR, Clerkin K, Sayer G, Uriel N.
    Clin Transplant; 2022 Dec 03; 36(12):e14808. PubMed ID: 36086937
    [Abstract] [Full Text] [Related]

  • 17. Real world experience with conversion from valganciclovir to letermovir for cytomegalovirus prophylaxis: Letermovir reverses leukopenia and avoids mycophenolate dose reduction.
    Jorgenson MR, Descourouez JL, Saddler CM, Smith JA, Odorico JS, Rice JP, Mandelbrot DA.
    Clin Transplant; 2023 Dec 03; 37(12):e15142. PubMed ID: 37755141
    [Abstract] [Full Text] [Related]

  • 18. Tailoring cytomegalovirus prophylaxis based on T cell immunity panel assessment in kidney transplant patients at high risk of cytomegalovirus.
    Servais AM, McMullen JS, Bowen R, Kleiboeker SB, Ulloa I, Duncan K, Miles CD.
    Transpl Infect Dis; 2024 Aug 03; 26(4):e14291. PubMed ID: 38708965
    [Abstract] [Full Text] [Related]

  • 19. A Case Report of Successful Use of Twice-Daily Letermovir in the Treatment of Resistant Cytomegalovirus in a Small Bowel Transplant Recipient.
    Joharji H, Alaidaros F, Koujan H, Hamad A, Almaghrabi RS, Zidan A, Broering D, Al-Jedai A.
    Transplant Proc; 2022 Aug 03; 54(6):1679-1681. PubMed ID: 35842318
    [Abstract] [Full Text] [Related]

  • 20. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
    Jung S, Michel M, Stamminger T, Michel D.
    BMC Infect Dis; 2019 May 08; 19(1):388. PubMed ID: 31068147
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.